Gradientech Expands QuickMIC® Clinical Use in Germany
9 februari, 08:59
Gradientech Expands QuickMIC® Clinical Use in Germany
The diagnostics company Gradientech, specialised in ultra-rapid antibiotic susceptibility testing (AST), today announces a long-term agreement with ELBLAB GmbH in Germany for the use of its QuickMIC® system. The agreement strengthens Gradientech’s presence in one of its key European markets and demonstrates its commitment to providing advanced diagnostic solutions to healthcare providers.
ELBLAB GmbH, Meissen, is a centre for laboratory medicine responsible for all laboratory services within the ELBLAND Kliniken Group. ELBLAND Kliniken is a major regional healthcare provider in Saxony, Germany, operating hospitals in Meißen, Radebeul, and Riesa, offering comprehensive inpatient and outpatient care.
At ELBLAB’s microbiology laboratory, QuickMIC® is integrated into routine clinical workflows to deliver rapid phenotypic AST results. The system is primarily used for critically ill patients, including those with sepsis or severe pneumonia, enabling an earlier transition from empirical antibiotic therapy to targeted treatment and thereby supporting high-quality patient care.
“We highly value the QuickMIC® system's ability to determine resistance from a native positive blood culture in just 3.5 hours, without time-consuming cultivation of the germs. In addition, the system's ability to measure actual MIC values rather than extrapolate results is a key advantage. This allows patients to receive targeted treatment at a very early stage, rather than just calculated treatment”, says Dr. med. Boris Rolinski, Managing Director and Chief Physician, Laboratory Medicine at ELBLAB GmbH.
QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.
Gradientech Expands QuickMIC® Clinical Use in Germany
9 februari, 08:59
Gradientech Expands QuickMIC® Clinical Use in Germany
The diagnostics company Gradientech, specialised in ultra-rapid antibiotic susceptibility testing (AST), today announces a long-term agreement with ELBLAB GmbH in Germany for the use of its QuickMIC® system. The agreement strengthens Gradientech’s presence in one of its key European markets and demonstrates its commitment to providing advanced diagnostic solutions to healthcare providers.
ELBLAB GmbH, Meissen, is a centre for laboratory medicine responsible for all laboratory services within the ELBLAND Kliniken Group. ELBLAND Kliniken is a major regional healthcare provider in Saxony, Germany, operating hospitals in Meißen, Radebeul, and Riesa, offering comprehensive inpatient and outpatient care.
At ELBLAB’s microbiology laboratory, QuickMIC® is integrated into routine clinical workflows to deliver rapid phenotypic AST results. The system is primarily used for critically ill patients, including those with sepsis or severe pneumonia, enabling an earlier transition from empirical antibiotic therapy to targeted treatment and thereby supporting high-quality patient care.
“We highly value the QuickMIC® system's ability to determine resistance from a native positive blood culture in just 3.5 hours, without time-consuming cultivation of the germs. In addition, the system's ability to measure actual MIC values rather than extrapolate results is a key advantage. This allows patients to receive targeted treatment at a very early stage, rather than just calculated treatment”, says Dr. med. Boris Rolinski, Managing Director and Chief Physician, Laboratory Medicine at ELBLAB GmbH.
QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.
Flat Capital
Nya bolåneregler
Analys
Fonder
ETF:er
Flat Capital
Nya bolåneregler
Analys
Fonder
ETF:er
Marknadsöversikt
1 DAG %
Senast
1 mån
